Study of Relatlimab in Combination With Nivolumab in Chinese Participants

Sponsor
Bristol-Myers Squibb
Study ID
NCT05498480
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Relatlimab — BIOLOGICAL
    Specified dose on specified days
  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and drug levels of relatlimab combined with nivolumab in Chinese participants with advanced solid tumors.

Key Dates

Start date
Jul 27, 2022
Status verified
Feb 2024
Primary completion
Jan 18, 2024
Completion
Jan 18, 2024

Study Design

Enrollment
6 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Relatlimab Dose 1 + Nivolumab
  • Experimental: Cohort 2: Relatlimab Dose 2 + Nivolumab

Primary Outcome Measure

Number of Participants with Adverse Events (AEs) [ Time Frame: Up to 123 Weeks ]

Related Studies